

## Zanubrutinib

ALTERNATE NAME: (7S)-4,5,6,7-Tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-

a]pyrimidine-3-carboxamide

(S)-Zanubrutinib BGB-3111 BGB3111

**CATALOG #**: B2512-1 1 mg B2512-5 5 mg

STRUCTURE:

**MOLECULAR FORMULA:**  $C_{27}H_{29}N_5O_3$ 

MOLECULAR WEIGHT: 471.56

**CAS NUMBER:** 1691249-45-2

APPEARANCE: White to off-white solid

PURITY: ≥98% by HPLC

**SOLUBILITY**: >50 mg/ml DMSO

**DESCRIPTION:** Zanubrutinib (BGB3111) is a potent, selective and orally available Btk inhibitor; displaysmuch more

restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib. BGB-3111 selectively binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen

receptor (BCR) signaling pathway.

**STORAGE TEMPERATURE:** -20°C. Protect from light

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure

**RELATED PRODUCTS:** 

Evobrutinib (B2379) ONO-4059 (B1283) BTK Inhibitor, PCI-32765 (2298) AVL-292 (Spebrutinib) (9413) Acalabrutinib (B1193) BTK Inhibitor, CNX-774 (2600)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.